These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38639534)

  • 1. The safety signal detection and analysis of monoclonal antibodies against SARS-CoV-2 based on real-world evidence - the suitable selectivity for different populations.
    Wang Y; Xu XW; Zhou S; Li JN
    Eur Rev Med Pharmacol Sci; 2024 Apr; 28(7):2943-2954. PubMed ID: 38639534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the post hoc effectiveness of tixagevimab-cilgavimab for prevention of SARS-CoV-2 infections in solid organ transplant recipients.
    Jordan SC; Joung SY; Wang M; Tran TA; Bravo M; Masoom H; Chang C; Mendez M; Sun N; Patel J; Kittleson M; Frias E; Prostko JC; Ebinger JE; Cheng S; Sobhani K
    Transpl Infect Dis; 2024 Feb; 26(1):e14182. PubMed ID: 37885435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world experience of tixagevimab-cilgavimab pre-exposure prophylaxis in orthotopic heart transplant recipients.
    Ordaya EE; Higgins EM; Vergidis P; Razonable RR; Beam E
    Transpl Infect Dis; 2023 Jun; 25(3):e14040. PubMed ID: 36847413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prevention of COVID-19 in High-Risk Patients Using Tixagevimab-Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center.
    Al-Obaidi MM; Gungor AB; Kurtin SE; Mathias AE; Tanriover B; Zangeneh TT
    Am J Med; 2023 Jan; 136(1):96-99. PubMed ID: 36181789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tixagevimab/Cilgavimab as SARS-CoV-2 Pre-Exposure Prophylaxis in Lung Transplant Recipients during the Omicron Wave: A Real-World Monocentric Experience.
    Cona A; Tavelli A; Agrenzano S; Hafeez N; Scianna G; Maria A; Marino F; Cruz E; Giorgio MD; Osorio E; Cucinella G; Luca A; Provenzani A; Vitulo P; Bertani A; Grossi PA; Mularoni A
    Microorganisms; 2024 Jul; 12(7):. PubMed ID: 39065204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased reporting of venous and arterial thromboembolic events reported with tixagevimab-cilgavimab for coronavirus disease 2019.
    Montastruc F; Lafaurie M; Flumian C; de Canecaude C
    Clin Microbiol Infect; 2023 Apr; 29(4):543.e1-543.e3. PubMed ID: 36464214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.
    Forte-Soto P; Albayaty M; Brooks D; Arends RH; Tillinghast J; Aksyuk AA; Bouquet J; Chen C; Gebre A; Kubiak RJ; Pilla Reddy V; Seegobin S; Streicher K; Templeton A; Esser MT
    J Infect Dis; 2023 May; 227(10):1153-1163. PubMed ID: 36683419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients.
    Lombardi A; Viero G; Villa S; Biscarini S; Palomba E; Azzarà C; Iannotti N; Mariani B; Genovese C; Tomasello M; Tonizzo A; Fava M; Valzano AG; Morlacchi LC; Donato MF; Castellano G; Cassin R; Carrabba M; Muscatello A; Gori A; Bandera A
    Biomedicines; 2023 May; 11(6):. PubMed ID: 37371635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-exposure Prophylaxis with Tixagevimab-cilgavimab did not Reduce Severity of COVID-19 in Lung Transplant Recipients with Breakthrough Infection.
    Sindu D; Razia D; Grief K; Cherrier L; Omar A; Walia R; Tokman S
    Transplant Direct; 2023 Jun; 9(6):e1485. PubMed ID: 37197016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
    Hirsch C; Park YS; Piechotta V; Chai KL; Estcourt LJ; Monsef I; Salomon S; Wood EM; So-Osman C; McQuilten Z; Spinner CD; Malin JJ; Stegemann M; Skoetz N; Kreuzberger N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD014945. PubMed ID: 35713300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-center review of pre-exposure prophylaxis with tixagevimab-cilgavimab in solid organ transplant recipients.
    Morado F; Davoudi R; Kawewat-Ho P; Nanda N; Cartus R; Shaikh SA
    Transpl Infect Dis; 2023 Aug; 25(4):e14086. PubMed ID: 37314092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Anti-SARS-CoV-2 Monoclonal Antibodies: An Updated Review.
    Ravi G; Eerike M; Konda VR; Bisoi D; Raj GM; Priyadarshini R; Mali KR; Chaliserry LF
    Monoclon Antib Immunodiagn Immunother; 2023 Apr; 42(2):77-94. PubMed ID: 37129306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis.
    Ordaya EE; Vergidis P; Razonable RR; Yao JD; Beam E
    J Clin Virol; 2023 Mar; 160():105382. PubMed ID: 36731147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tixagevimab/cilgavimab for the prevention of COVID-19 in solid organ transplant recipients.
    Eribes E; Votruba C; Tinkham T; Huang A; Ilges D; Kunze K; Hudson M
    Clin Transplant; 2024 Feb; 38(2):e15261. PubMed ID: 38375915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era.
    Sridhara S; Gungor AB; Erol HK; Al-Obaidi M; Zangeneh TT; Bedrick EJ; Ariyamuthu VK; Shetty A; Qannus AA; Mendoza K; Murugapandian S; Gupta G; Tanriover B
    PLoS One; 2023; 18(4):e0279326. PubMed ID: 37115780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19.
    Zou J; Jing F
    Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies.
    Bruel T; Stéfic K; Nguyen Y; Toniutti D; Staropoli I; Porrot F; Guivel-Benhassine F; Bolland WH; Planas D; Hadjadj J; Handala L; Planchais C; Prot M; Simon-Lorière E; André E; Baele G; Cuypers L; Mouthon L; Mouquet H; Buchrieser J; Sève A; Prazuck T; Maes P; Terrier B; Hocqueloux L; Schwartz O
    Cell Rep Med; 2022 Dec; 3(12):100850. PubMed ID: 36450283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis.
    Khorramnia S; Navidi Z; Orandi A; Iravani MM; Orandi A; Malekabad ES; Moghadam SHP
    Clin Transplant Res; 2024 Jun; 38(2):136-144. PubMed ID: 38904088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period.
    Fomina DS; Lebedkina MS; Iliukhina AA; Kovyrshina AV; Shelkov AY; Andreev SS; Chernov AA; Dolzhikova IV; Kruglova TS; Andrenova GV; Tukhvatulin AI; Shcheblyakov DV; Karaulov AV; Lysenko MA; Logunov DY; Gintsburg AL
    Front Immunol; 2023; 14():1259725. PubMed ID: 37928549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data.
    Young-Xu Y; Epstein L; Marconi VC; Davey V; Korves C; Zwain G; Smith J; Cunningham F; Bonomo RA; Ginde AA
    mBio; 2023 Aug; 14(4):e0102423. PubMed ID: 37535398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.